@article{3029771,
    title = "Investigational Drug Treatments for Triple-Negative Breast Cancer",
    author = "Damaskos, Christos and Garmpis, Nikolaos and Garmpi, Anna and and Nikolettos, Konstantinos and Sarantis, Panagiotis and Georgakopoulou, and Vasiliki E. and Nonni, Afroditi and Schizas, Dimitrios and Antoniou, and Efstathios A. and Karamouzis, V, Michalis and Nikolettos, Nikos and and Kontzoglou, Konstantinos and Patsouras, Alexandros and Voutyritsa, and Errika and Syllaios, Athanasios and Koustas, Evangelos and Trakas, and Nikolaos and Dimitroulis, Dimitrios",
    journal = "International Journal of Person-Centered Medicine",
    year = "2021",
    volume = "11",
    number = "7",
    publisher = "MDPI",
    issn = "2043-7730, 2043-7749",
    doi = "10.3390/jpm11070652",
    keywords = "novel therapeutic strategies; immunotherapy; targeted therapies;
PI3kb/mTOR inhibitors; PARP inhibitors; histone deacetylase inhibitors",
    abstract = "Triple-negative breast cancer (TNBC) is an aggressive subtype of breast
cancer (BC) and accounts for 10-20% of cases. Due to the lack of
expression of several receptors, hormone therapy is largely ineffective
for treatment purposes. Nevertheless, TNBC often responds very well to
chemotherapy, which constitutes the most often recommended treatment.
New beneficial targeted therapies are important to be investigated in
order to achieve enhanced outcomes in patients with TNBC. This review
will focus on recent therapeutic innovations for TNBC, focusing on
various inhibitors such as phosphoinositide 3-kinase (PI3K) pathway
inhibitors, poly-ADP-ribosyl polymerase (PARP) inhibitors, aurora kinase
inhibitors, histone deacetylase inhibitors (HDACIs), and immune
checkpoint inhibitors."
}